In addition to the above mentioned trials, two phase III trials of pembrolizumab at a fixed dose of 200 mg i.v. every 3 weeks for up to 35 treatments is also being compared in the first line setting vs. platinum based chemotherapy in PD-L1 positive and PD-L1 strong positive NSCLC patients (Keynote 042, NCT02220894 and Keynote 024, NCT02142738) (Table 2). This evidence concerns the gene CD274 and non-small cell lung carcinoma.